Annals of Surgical Oncology, Vol 4, Issue 1 64-69, Copyright © 1997 by Society of Surgical Oncology

ARTICLES

Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor

A. F. Olieman, R. J. van Ginkel, H. J. Hoekstra, E. L. Mooyaart, W. M. Molenaar and H. S. Koops
Department of Surgical Oncology, University Hospital Groningen, The Netherlands.

BACKGROUND: Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), and melphalan is associated with a dramatic anti-tumor effect in which the neo-vascularization of the tumor is supposed to be the major target. The aim of the present study was to correlate the angiographic findings with the pathological response in patients undergoing HILP for locally advanced soft-tissue sarcoma. PATIENTS AND METHODS: Twenty-five patients, 14 male and 11 female, mean age 47 years (range 18-80) were studied. Angiographies were performed before and a median period of 7 weeks (range 4-14 weeks) after HILP. Eight weeks after perfusion, the residual tumor mass was resected and pathologically examined. The changes in tumor vascularization after treatment were scored and compared with the pathological response. RESULTS: All baseline angiograms showed a hypervascular tumor. After HILP, a normal angiography result (NA) was observed in 18 patients (72%) and an abnormal angiography result (AA) was observed in seven patients (28%). All patients with an NA showed a pathologically complete response (pCR) or a pathological partial response with > 90% necrosis of the tumor. Of seven patients with an AA, pathological examination showed a pCR in one patient, 10-50% viable tumor volume in four patients, and no pathological response after perfusion in two patients. A good correlation was seen between angiographic and pathological classification (p < 0.001). CONCLUSION: An angiography performed after hyperthermic isolated limb perfusion with TNF-alpha and melphalan provides a good indication, regardless of whether a good pathological response is expected.

This article has been cited by other articles:

				M. L. Hoven-Gondrie, K. M. J. Thijssens, J. J. A. M. Van den Dungen, J. Loonstra, R. J. van Ginkel, and H. J. Hoekstra Long-Term Locoregional Vascular Morbidity After Isolated Limb Perfusion and External-Beam Radiotherapy for Soft Tissue Sarcoma of the Extremity Ann. Surg. Oncol., July 1, 2007; 14(7): 2105 - 2112. [Abstract] [Full Text] [PDF]

				J. H. W. de Wilt and a. J. F. Thompson Is there a Role for Isolated Limb Perfusion With Tumor Necrosis Factor in Patients With Melanoma? Ann. Surg. Oncol., February 1, 2004; 11(2): 119 - 121. [Full Text] [PDF]

				C. Halin, V. Gafner, M. E. Villani, L. Borsi, A. Berndt, H. Kosmehl, L. Zardi, and D. Neri Synergistic Therapeutic Effects of a Tumor Targeting Antibody Fragment, Fused to Interleukin 12 and to Tumor Necrosis Factor {alpha} Cancer Res., June 15, 2003; 63(12): 3202 - 3210. [Abstract] [Full Text] [PDF]

				U. Stein, K. Jurchott, M. Schlafke, and P. Hohenberger Expression of Multidrug Resistance Genes MVP, MDR1, and MRP1 Determined Sequentially Before, During, and After Hyperthermic Isolated Limb Perfusion of Soft Tissue Sarcoma and Melanoma Patients J. Clin. Oncol., August 1, 2002; 20(15): 3282 - 3292. [Abstract] [Full Text] [PDF]

				J. Friedl, M. Puhlmann, D. L. Bartlett, S. K. Libutti, E. N. Turner, M. F. X. Gnant, and H. R. Alexander Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF Blood, July 30, 2002; 100(4): 1334 - 1339. [Abstract] [Full Text] [PDF]

				M. F. X. Gnant, A. C. Berger, J. Huang, M. Puhlmann, P. C. Wu, M. J. Merino, D. L. Bartlett, H. Richard Alexander, and S. K. Libutti Sensitization of Tumor Necrosis Factor {{alpha}}-resistant Human Melanoma by Tumor-specific in Vivo Transfer of the Gene Encoding Endothelial Monocyte-activating Polypeptide II Using Recombinant Vaccinia Virus Cancer Res., September 1, 1999; 59(18): 4668 - 4674. [Abstract] [Full Text] [PDF]

				B. E. C. Plaat, W. M. Molenaar, M. F. Mastik, J. Koudstaal, E. v. den Berg, H. S. Koops, and H. J. Hoekstra Hyperthermic Isolated Limb Perfusion with Tumor Necrosis Factor-{{alpha}} and Melphalan in Patients with Locally Advanced Soft Tissue Sarcomas: Treatment Response and Clinical Outcome Related to Changes in Proliferation and Apoptosis Clin. Cancer Res., July 1, 1999; 5(7): 1650 - 1657. [Abstract] [Full Text] [PDF]

				A. F. T. Olieman, D. Lienard, A. M. M. Eggermont, B. B. R. Kroon, F. J. Lejeune, H. J. Hoekstra, and H. S. Koops Hyperthermic Isolated Limb Perfusion With Tumor Necrosis Factor {alpha}, Interferon Gamma, and Melphalan for Locally Advanced Nonmelanoma Skin Tumors of the Extremities: A Multicenter Study Arch Surg, March 1, 1999; 134(3): 303 - 307. [Abstract] [Full Text] [PDF]

				P. C. Wu, H. R. Alexander, J. Huang, P. Hwu, M. Gnant, A. C. Berger, E. Turner, O. Wilson, and S. K. Libutti In Vivo Sensitivity of Human Melanoma to Tumor Necrosis Factor (TNF)-{{alpha}} Is Determined by Tumor Production of the Novel Cytokine Endothelial-Monocyte Activating Polypeptide II (EMAPII) Cancer Res., January 1, 1999; 59(1): 205 - 212. [Abstract] [Full Text] [PDF]